Skip to main content
MANE
NYSE Life Sciences

Suvretta Capital Management and Affiliates Invest $30M in Veradermics via Pre-Funded Warrants

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$114.5
Mkt Cap
$4.728B
52W Low
$32
52W High
$116
52W Position info
258% above low
Off High info
1.3% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

MANE has more than doubled off its 52-week low of $32 on elevated volume (1.9× avg).

Summary

Suvretta Capital Management and its affiliates invested $30 million in Veradermics through pre-funded warrants as part of a recent private placement, signaling continued institutional support after positive clinical trial results and a successful capital raise.


Key Events · Ownership and Investor Activity · MANE

  • Institutional Investment in Private Placement

    Suvretta Capital Management and its affiliated funds acquired 300,000 pre-funded warrants in Veradermics for approximately $30 million.

  • Part of Recent Financing Round

    This investment, dated May 1, 2026, was made as part of the company's previously announced private placement and public offering, which raised $388.8 million.

  • Significant Beneficial Ownership Maintained

    Suvretta Capital Management and Aaron Cowen now report 9.9% beneficial ownership, while Averill Master Fund holds 8.7%, reflecting continued institutional backing.


Analysis · MANE · Life Sciences

Suvretta Capital Management, along with its affiliated funds Averill Master Fund and Averill Madison Master Fund, has acquired approximately $30 million worth of pre-funded warrants in Veradermics. This investment was part of the company's recent private placement, which closed on May 1, 2026, concurrent with a larger public offering. The acquisition of these warrants, effectively priced at $100 per share (matching the public offering price), demonstrates continued institutional confidence in Veradermics following its positive Phase 2/3 clinical trial data and successful capital raise. This investment, made while the stock trades near its 52-week high, underscores institutional belief in Veradermics' valuation and future prospects. The funds now collectively hold significant stakes, with Suvretta and Aaron Cowen reporting 9.9% beneficial ownership.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MANE was trading at $114.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $32.00 to $116.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MANE - Latest Insights

MANE
Nov 13, 2026, 5:39 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $129.66
Real-time Price: $126.14 info
Change: -$3.52 (-3%) info
Market Cap: $5.28B info
MANE
Nov 10, 2026, 4:57 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $148.44
Real-time Price: $126.14 info
Change: -$22.30 (-15%) info
Market Cap: $5.28B info
MANE
Nov 10, 2026, 8:54 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $142.72
Real-time Price: $126.14 info
Change: -$16.58 (-12%) info
Market Cap: $5.28B info
MANE
Nov 09, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $142.00
Real-time Price: $126.14 info
Change: -$15.86 (-11%) info
Market Cap: $5.28B info
MANE
Nov 08, 2026, 6:00 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $139.33
Real-time Price: $126.14 info
Change: -$13.19 (-9%) info
Market Cap: $5.28B info